Hereditary Dystonia — from DYT1-TOR1A (where deep brain stimulation transforms outcomes) to dopa-responsive dystonia (where a single levodopa tablet can change a wheelchair-bound child into a walker), molecular diagnosis unlocks the correct treatment.
Whole genome sequencing evaluates all hereditary dystonia genes — TOR1A, GCH1, TH, SGCE, THAP1, KMT2B, and others — distinguishing treatable dopa-responsive dystonia from other forms that require different management approaches.
Hereditary Dystonia
Hereditary dystonias are a genetically heterogeneous group of movement disorders characterized by sustained or intermittent involuntary muscle contractions causing abnormal postures and movements. Over 30 genetic forms have been identified (DYT1 through DYT28+). The two most clinically important are DYT1 (TOR1A GAG deletion, the most common primary dystonia in Ashkenazi Jews with ~1:3,000 carrier frequency) and dopa-responsive dystonia (DRD, most commonly caused by GCH1 variants — DYT5a, or TH variants — DYT5b).
Dopa-responsive dystonia (DRD) is one of the most dramatically treatable neurological conditions. GCH1 variants (autosomal dominant with reduced penetrance, particularly in males) impair tetrahydrobiopterin synthesis, reducing dopamine production in the basal ganglia. Children present with progressive lower-limb dystonia, typically with diurnal fluctuation (worse in the evening, improved after sleep) — a clinical clue that is often missed. DRD responds completely and sustainably to low-dose levodopa — often 50-100mg daily — with dramatic improvement within days. Many DRD patients are misdiagnosed as cerebral palsy for years, remaining wheelchair-bound while the effective treatment costs pennies per day.
DYT1 dystonia (TOR1A GAG deletion) affects approximately 1 in 9,000-16,000 Ashkenazi Jews and typically presents in childhood with limb dystonia that may generalize. Unlike DRD, DYT1 does not respond well to levodopa. Deep brain stimulation (DBS) of the globus pallidus internus is highly effective for DYT1 — producing sustained 50-90% reduction in dystonia severity. DBS outcomes in DYT1 are among the best of any dystonia subtype, and early DBS (before fixed skeletal contractures develop) produces superior results. Molecular DYT1 confirmation identifies patients with the best DBS prognosis.
DRD/GCH1 may be the most treatable missed diagnosis in pediatric neurology. Any child with dystonia — especially with diurnal fluctuation or progressive gait difficulty — should receive a therapeutic levodopa trial. Many 'cerebral palsy' diagnoses actually have GCH1 variants.
The dystonia gene determines whether levodopa, deep brain stimulation, or other approaches are indicated. DRD misdiagnosed as cerebral palsy means years of unnecessary disability — a single genetic test changes everything.
Dopa-responsive dystonia patients misdiagnosed as cerebral palsy spend years in wheelchairs — while the treatment costs pennies per day
Multiple published case series document DRD patients misdiagnosed as cerebral palsy for 10-30 years. The diagnostic clue — diurnal fluctuation (worse in the afternoon/evening, improved after sleep) — is often not elicited in clinical history. A therapeutic levodopa trial should be attempted in any child with unexplained dystonia, but is frequently not performed because the clinician is confident in the CP diagnosis. WGS identifies GCH1 and TH variants definitively, triggering the levodopa trial that transforms the patient's life from wheelchair-dependent to independently mobile.
DBS outcomes are best for DYT1 — molecular TOR1A confirmation identifies patients with the highest probability of DBS success
Deep brain stimulation response varies dramatically by dystonia etiology. DYT1 (TOR1A) patients achieve 50-90% reduction in dystonia severity scores — among the best DBS outcomes in movement disorders. Secondary and complex dystonias typically achieve only 20-30% improvement. Molecular TOR1A confirmation identifies the patients most likely to benefit from DBS, supporting the surgical decision and setting appropriate expectations. Additionally, early DBS before fixed skeletal deformities develop produces superior outcomes — another argument for early molecular diagnosis.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Hereditary Dystonia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
